Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on the efficacy of immune checkpoint inhibitor (ICI)-based therapy in patients with chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC).
Methods: A total of 155 patients with CHB-related HCC who received ICI-based therapy (in the Department of Hepatology, Tianjin Second People's Hospital and Department of Hepatobiliary Oncology, Tianjin Medical University Cancer Institute & Hospital) between April 2021 and December 2023 were evaluated. Patients were divided into two groups: MASLD concurrent with CHB [MASLD-CHB] ( = 38), and CHB ( = 117).
Results: The median progression-free survival (PFS, 6.9 months 9.3 months; = 0.001), progressive disease (57.89% 37.61%; = 0.028), and disease control rate (42.11% 62.39%; = 0. 028) in the MASLD-CHB group were significantly worse than the CHB group. The median overall survival was not attained. The percentage of CD4+PD1+ (17. 56% 8.89%; < 0.001) and CD8+PD1+ T cells (10.50% 7.42%; = 0.005) in patient samples from the MASLD-CHB group were significantly higher than the CHB group. Concurrent MASLD [hazard ratio (HR) = 1.921; 95% CI, 1.138-3.245; = 0.015] and alpha-fetoprotein levels after 3 months of treatment (HR = 2.412; 95% CI, 1.360-4.279; = 0.003) were independent risk factors for PFS in all patients.
Conclusions: ICI-based therapy in patients with CHB-related HCC and concurrent MASLD resulted in poorer efficacy and shorter PFS compared to patients with CHB-related HCC alone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414222 | PMC |
| http://dx.doi.org/10.20892/j.issn.2095-3941.2024.0048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset.
Clin Exp Metastasis
September 2025
Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Recent years have seen the development and advent of novel combinatorial strategies based on immunotherapy, and immune checkpoint inhibitor (ICI) - based treatment has established itself as a mainstay in the treatment of metastatic urothelial carcinoma (UC). Herein, we aimed to validate the prognostic value of a previously developed score, the Prognostic Immunotherapy Score (PIS), including female sex, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) and liver metastases, in patients treated with pembrolizumab for advanced UC from the ARON-2 dataset. We retrospectively analyzed clinical data from Metastatic UC patients diagnosed at age ≥ 18 years.
View Article and Find Full Text PDFPrognostic impact of immune-related adverse events on combination immune checkpoint/tyrosine kinase inhibition for metastatic renal cancer.
Cancer Res Commun
September 2025
University of Tsukuba, Tsukuba, Japan.
Immune checkpoint inhibitor (ICI) combinations and tyrosine kinase inhibitor (TKI) use are standard for metastatic renal cell carcinoma (mRCC), leading to improved outcomes. However, due to a lack of predictive biomarkers, the presence or absence of immune-related adverse events (irAEs) is currently employed as a predictive factor in clinical practice. To elucidate the impact of irAEs on efficacy, a cohort of mRCC patients who received ICI-based combination therapy as initial treatment was analyzed.
View Article and Find Full Text PDFROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer.
Biomaterials
September 2025
Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology (HUST), Wuhan, 430074, China.
Bladder cancer remains a formidable challenge, especially for patients who fail to respond adequately to immune checkpoint inhibitors (ICIs). The suboptimal efficacy of current treatments underscores an urgent need for more effective immunomodulatory strategies. Here, we propose a ROS-responsive resiquimod (R848) prodrug (R-P) that improves drug delivery and reshapes the immunosuppressive tumor microenvironment.
View Article and Find Full Text PDFExplainable machine learning models based on clinical trial surrogate outcomes for predicting overall survival in head and neck cancers.
ESMO Open
September 2025
Department of Medicine, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA. Electronic address:
Background: This study aimed to evaluate the relationship between surrogate efficacy outcomes and overall survival (OS) in clinical trials for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), and to develop a predictive model for OS that incorporates these surrogate outcomes while accounting for baseline patient characteristics.
Materials And Methods: Data were systematically collected from first-line trials published between January 2010 and March 2025 for R/M HNSCC. Five machine learning models were assessed to predict OS based on surrogate outcomes [objective response rate (ORR), disease control rate, progression free survival (PFS), duration of response, 1-year OS rate] and patient characteristics [human papillomavirus (HPV) status, Eastern Cooperative Oncology Group (ECOG) performance status, programmed death-ligand 1 (PD-L1) expression].
Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases.
Lung Cancer
September 2025
Department of Pulmonary Diseases, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address:
Background: Brain metastases (BM) are common in non-small cell lung cancer (NSCLC). Although guidelines recommend baseline BM screening in asymptomatic patients, its benefit remains unproven. Routine imaging burdens healthcare systems and patients.
View Article and Find Full Text PDF